March 1 (Reuters) - Agios Pharmaceuticals Inc :
* AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR TIBSOVO® (IVOSIDENIB TABLETS) FOR PATIENTS WITH PREVIOUSLY TREATED IDH1-MUTANT CHOLANGIOCARCINOMA
* AGIOS PHARMACEUTICALS - CO HAS REQUESTED PRIORITY REVIEW FOR APPLICATION OF TIBSOVO, WHICH, IF GRANTED, COULD RESULT IN A SIX-MONTH REVIEW PROCESS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)
* AGIOS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO FDA FOR TIBSOVO® (IVOSIDENIB TABLETS) FOR PATIENTS WITH PREVIOUSLY TREATED IDH1-MUTANT CHOLANGIOCARCINOMA
* AGIOS PHARMACEUTICALS - CO HAS REQUESTED PRIORITY REVIEW FOR APPLICATION OF TIBSOVO, WHICH, IF GRANTED, COULD RESULT IN A SIX-MONTH REVIEW PROCESS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;)